DLEC1 Activators
DLEC1 activators are chemicals that serve to indirectly augment the functional activity of the DLEC1 protein, which is implicated in the regulation of cellular processes pertinent to tumor suppression. Forskolin, an adenylyl cyclase activator, promotes the increase of cAMP within the cell, which in turn can enhance protein kinase A (PKA) activity and potentially influence the phosphorylation state of proteins that interact with or are part of the same pathway as DLEC1, thereby improving DLEC1's tumor suppressive functions. Genistein's role as a tyrosine kinase inhibitor may alleviate competing signals from tyrosine kinase-associated pathways, allowing DLEC1-related pathways to become more prominent in cellular signaling. Similarly, sphingosine-1-phosphate (S1P) can activate its own receptors and initiate signaling cascades that intersect with DLEC1 activity, potentially amplifying its role in the cell. Compounds such as Thapsigargin and PMA act through increasing intracellular calcium levels and activating protein kinase C (PKC), respectively, both of which could modify the cellular environment in a way that enhances DLEC1's activity.
The second group of DLEC1 activators includes those that impact specific kinase pathways, such as LY294002 and Wortmannin, which are PI3K inhibitors. By dampening PI3K signaling, these compounds may induce a compensatory upregulation of DLEC1-involved pathways. MAPK pathway inhibitors like SB203580 and U0126 also modulate cellular signaling, potentially favoring the enhancement of DLEC1's function. A23187 (Calcimycin) and staurosporine alter intracellular calcium levels and inhibit a broad spectrum of protein kinases, respectively, which can lead to the activation of calcium-dependent processes or the selective enhancement of pathways where DLEC1 is involved. Epigallocatechin gallate (EGCG), with its kinase inhibitory properties, may also modulate signaling in a manner that favors DLEC1 pathway activation.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Forskolin | 66575-29-9 | sc-3562 sc-3562A sc-3562B sc-3562C sc-3562D | 5 mg 50 mg 1 g 2 g 5 g | $78.00 $153.00 $740.00 $1413.00 $2091.00 | 73 | |
Forskolin activates adenylyl cyclase, leading to an increase in intracellular cAMP levels. Elevated cAMP activates PKA, which can phosphorylate various proteins potentially involved in the same pathways DLEC1 is part of, thereby enhancing DLEC1 function. | ||||||
Genistein | 446-72-0 | sc-3515 sc-3515A sc-3515B sc-3515C sc-3515D sc-3515E sc-3515F | 100 mg 500 mg 1 g 5 g 10 g 25 g 100 g | $45.00 $164.00 $200.00 $402.00 $575.00 $981.00 $2031.00 | 46 | |
Genistein, a tyrosine kinase inhibitor, may reduce competitive signaling from tyrosine kinases, which can lead to a relative increase in pathways where DLEC1 is active, indirectly enhancing the functional activity of DLEC1. | ||||||
D-erythro-Sphingosine-1-phosphate | 26993-30-6 | sc-201383 sc-201383D sc-201383A sc-201383B sc-201383C | 1 mg 2 mg 5 mg 10 mg 25 mg | $165.00 $322.00 $570.00 $907.00 $1727.00 | 7 | |
Sphingosine-1-phosphate binds to its receptors, initiating signaling cascades that can modulate intracellular processes related to DLEC1 activity, leading to an enhancement of DLEC1's functional role in the cell. | ||||||
Thapsigargin | 67526-95-8 | sc-24017 sc-24017A | 1 mg 5 mg | $136.00 $446.00 | 114 | |
Thapsigargin leads to an increase in intracellular calcium by inhibiting the sarcoplasmic/endoplasmic reticulum Ca2+ ATPase (SERCA). Elevated calcium levels can activate calcium-dependent pathways that DLEC1 may be involved in, enhancing its activity. | ||||||
PMA | 16561-29-8 | sc-3576 sc-3576A sc-3576B sc-3576C sc-3576D | 1 mg 5 mg 10 mg 25 mg 100 mg | $41.00 $132.00 $214.00 $500.00 $948.00 | 119 | |
PMA directly activates protein kinase C (PKC), which could phosphorylate and thereby enhance the functional activity of DLEC1 by enhancing related signaling pathways. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY294002 inhibits PI3K, altering downstream signaling pathways. This inhibition could lead to a compensatory upregulation of alternative pathways in which DLEC1 is involved, indirectly enhancing DLEC1 functional activity. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
Wortmannin is another PI3K inhibitor that can modulate downstream signaling, potentially leading to enhanced DLEC1 activity by shifting the balance of intracellular signaling towards pathways that DLEC1 is a part of. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
SB203580 is a p38 MAPK inhibitor. By inhibiting p38 MAPK, it can shift signaling towards other pathways, potentially enhancing those where DLEC1 is involved and leading to increased DLEC1 activity. | ||||||
A23187 | 52665-69-7 | sc-3591 sc-3591B sc-3591A sc-3591C | 1 mg 5 mg 10 mg 25 mg | $55.00 $131.00 $203.00 $317.00 | 23 | |
A23187 directly increases intracellular calcium levels, potentially activating calcium-dependent signaling pathways that could enhance DLEC1 activity. | ||||||
Staurosporine | 62996-74-1 | sc-3510 sc-3510A sc-3510B | 100 µg 1 mg 5 mg | $82.00 $153.00 $396.00 | 113 | |
Staurosporine is a broad-spectrum protein kinase inhibitor. By inhibiting certain kinases, it may selectively activate pathways or processes where DLEC1 is involved, leading to enhanced activity of DLEC1. | ||||||